185 related articles for article (PubMed ID: 16539384)
1. Assessment of in vitro and in vivo activities in the National Cancer Institute's anticancer screen with respect to chemical structure, target specificity, and mechanism of action.
Huang R; Wallqvist A; Covell DG
J Med Chem; 2006 Mar; 49(6):1964-79. PubMed ID: 16539384
[TBL] [Abstract][Full Text] [Related]
2. Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action.
Huang R; Wallqvist A; Thanki N; Covell DG
Pharmacogenomics J; 2005; 5(6):381-99. PubMed ID: 16103895
[TBL] [Abstract][Full Text] [Related]
3. Web-based tools for mining the NCI databases for anticancer drug discovery.
Fang X; Shao L; Zhang H; Wang S
J Chem Inf Comput Sci; 2004; 44(1):249-57. PubMed ID: 14741034
[TBL] [Abstract][Full Text] [Related]
4. Predictive statistics and artificial intelligence in the U.S. National Cancer Institute's Drug Discovery Program for Cancer and AIDS.
Weinstein JN; Myers T; Buolamwini J; Raghavan K; van Osdol W; Licht J; Viswanadhan VN; Kohn KW; Rubinstein LV; Koutsoukos AD
Stem Cells; 1994 Jan; 12(1):13-22. PubMed ID: 8142917
[TBL] [Abstract][Full Text] [Related]
5. Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations.
Fojo T; Farrell N; Ortuzar W; Tanimura H; Weinstein J; Myers TG
Crit Rev Oncol Hematol; 2005 Jan; 53(1):25-34. PubMed ID: 15607933
[TBL] [Abstract][Full Text] [Related]
6. Anticancer metal compounds in NCI's tumor-screening database: putative mode of action.
Huang R; Wallqvist A; Covell DG
Biochem Pharmacol; 2005 Apr; 69(7):1009-39. PubMed ID: 15763539
[TBL] [Abstract][Full Text] [Related]
7. Characterization of anticancer agents by their growth inhibitory activity and relationships to mechanism of action and structure.
Keskin O; Bahar I; Jernigan RL; Beutler JA; Shoemaker RH; Sausville EA; Covell DG
Anticancer Drug Des; 2000 Apr; 15(2):79-98. PubMed ID: 10901296
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of 11-substituted 6-aminobenzo[c]phenanthridine derivatives, a new class of antitumor agents.
Kock I; Heber D; Weide M; Wolschendorf U; Clement B
J Med Chem; 2005 Apr; 48(8):2772-7. PubMed ID: 15828815
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, antitumour activity and structure-activity relationships of 5H-benzo[b]carbazoles.
Asche C; Frank W; Albert A; Kucklaender U
Bioorg Med Chem; 2005 Feb; 13(3):819-37. PubMed ID: 15653349
[TBL] [Abstract][Full Text] [Related]
10. Semisynthesis and in vitro anticancer activities of andrographolide analogues.
Jada SR; Subur GS; Matthews C; Hamzah AS; Lajis NH; Saad MS; Stevens MF; Stanslas J
Phytochemistry; 2007 Mar; 68(6):904-12. PubMed ID: 17234223
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity of the novel glutathione-activated thiopurine prodrugs cis-AVTP [cis-6-(2-acetylvinylthio)purine] and trans-AVTG [trans-6-(2-acetylvinylthio)guanine] results from the National Cancer Institute's anticancer drug screen.
Gunnarsdottir S; Elfarra AA
Drug Metab Dispos; 2004 Mar; 32(3):321-7. PubMed ID: 14977866
[TBL] [Abstract][Full Text] [Related]
12. NCI's anticancer drug screening program may not be selecting for clinically active compounds.
Brown JM
Oncol Res; 1997; 9(5):213-5. PubMed ID: 9306428
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents.
Adams BK; Ferstl EM; Davis MC; Herold M; Kurtkaya S; Camalier RF; Hollingshead MG; Kaur G; Sausville EA; Rickles FR; Snyder JP; Liotta DC; Shoji M
Bioorg Med Chem; 2004 Jul; 12(14):3871-83. PubMed ID: 15210154
[TBL] [Abstract][Full Text] [Related]
14. Anticancer activity of selected phenolic compounds: QSAR studies using ridge regression and neural networks.
Nandi S; Vracko M; Bagchi MC
Chem Biol Drug Des; 2007 Nov; 70(5):424-36. PubMed ID: 17949360
[TBL] [Abstract][Full Text] [Related]
15. Evaluating chemical structure similarity as an indicator of cellular growth inhibition.
Wallqvist A; Huang R; Thanki N; Covell DG
J Chem Inf Model; 2006; 46(1):430-7. PubMed ID: 16426077
[TBL] [Abstract][Full Text] [Related]
16. The usefulness of cyclic diamidines with different core-substituents as antitumor agents.
Spychała J
Bioorg Chem; 2008 Aug; 36(4):183-9. PubMed ID: 18571215
[TBL] [Abstract][Full Text] [Related]
17. Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities.
Rabow AA; Shoemaker RH; Sausville EA; Covell DG
J Med Chem; 2002 Feb; 45(4):818-40. PubMed ID: 11831894
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of indenoisoquinoline topoisomerase I inhibitors using a hollow fiber assay.
Morrell A; Jayaraman M; Nagarajan M; Fox BM; Meckley MR; Ioanoviciu A; Pommier Y; Antony S; Hollingshead M; Cushman M
Bioorg Med Chem Lett; 2006 Aug; 16(16):4395-9. PubMed ID: 16750365
[TBL] [Abstract][Full Text] [Related]
19. Linking tumor cell cytotoxicity to mechanism of drug action: an integrated analysis of gene expression, small-molecule screening and structural databases.
Covell DG; Wallqvist A; Huang R; Thanki N; Rabow AA; Lu XJ
Proteins; 2005 May; 59(3):403-33. PubMed ID: 15778971
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of anticancer activity of 2-arylamino-6-trifluoromethyl-3-(hydrazonocarbonyl)pyridines.
Onnis V; Cocco MT; Fadda R; Congiu C
Bioorg Med Chem; 2009 Sep; 17(17):6158-65. PubMed ID: 19679483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
